Yvonne Hui, serving as the Principal Accounting Officer at Phreesia, Inc. (NASDAQ:PHR), completed the sale of 1,371 shares of common stock on July 6, 2026. The transaction generated a total value of $14,861, with each share sold at a price of $10.84. This specific transaction was executed in accordance with a Rule 10b5-1 trading plan that Ms. Hui adopted on January 15, 2026. Following the completion of this sale, Ms. Hui maintains direct ownership of 23,908 shares of Phreesia common stock.
The sale occurs against a backdrop of recent market performance for the healthcare technology company. According to InvestingPro data, Phreesia's stock has posted a 7.87% return over the past week. The company is currently trading at $10.95, reflecting a market capitalization of $674 million. InvestingPro analysis suggests that PHR may currently be undervalued, with 14 additional ProTips available to subscribers on the platform.
Phreesia Inc. recently reported its financial results for the first quarter of fiscal year 2027, demonstrating performance that exceeded analyst expectations. The company reported earnings per share (EPS) of $0.05, significantly surpassing the forecasted $0.01. Revenue for the quarter reached $130.9 million, slightly above the consensus estimate of $130.1 million. Additionally, adjusted EBITDA came in at $30.5 million, exceeding the expected $28.4 million.
Following these financial disclosures, several financial institutions have updated their ratings and price targets for Phreesia. DA Davidson reiterated its Buy rating on the stock, setting a price target of $14.00. Citizens maintained its Market Perform rating. In contrast, Piper Sandler downgraded Phreesia from Overweight to Neutral and lowered its price target from $23 to $12, citing a shift in profitability. Truist Securities raised its price target to $12.00 from $11.00, while maintaining a Hold rating. Truist noted that revenue estimates for fiscal years 2027 and 2028 remain relatively unchanged.
Management has maintained its full-year fiscal 2027 revenue guidance, which implies 1% organic revenue growth at the midpoint. These developments highlight varying analyst perspectives on Phreesia's financial performance and future outlook.
Key Points
- Principal Accounting Officer Yvonne Hui executed a sale of 1,371 shares under a pre-existing Rule 10b5-1 plan, retaining 23,908 shares post-transaction.
- Phreesia reported first-quarter fiscal 2027 results that surpassed consensus estimates for earnings per share, revenue, and adjusted EBITDA.
- Analyst sentiment remains divided, with DA Davidson maintaining a Buy rating and Piper Sandler downgrading the stock to Neutral, reflecting differing views on profitability and valuation.
Risks and Uncertainties
- Divergent analyst price targets and ratings suggest uncertainty regarding the company's near-term valuation, with targets ranging from $12.00 to $14.00, indicating potential volatility in the healthcare technology sector.
- The downgrade by Piper Sandler, citing a shift in profitability, introduces risk regarding future earnings trajectories and market confidence in the company's growth model.
- Management's guidance implies only 1% organic revenue growth at the midpoint for fiscal 2027, which may signal constrained expansion opportunities within the broader logistics and healthcare services market.